ONCO
Onconetix, Inc.1.9350
-0.0350-1.78%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
3.01MP/E (TTM)
0.00Basic EPS (TTM)
1229.73Dividend Yield
0%Recent Filings
8-K
Onconetix acquires Realbotix robots
Onconetix signed a share exchange agreement on February 11, 2026, to acquire Realbotix LLC, a U.S.-based maker of AI-powered humanoid robots for service and healthcare, from Simulacra in an all-stock deal. Seller gets 75-90% of fully diluted shares based on Onconetix's net cash at closing, minimum $12.5M required. Deal awaits shareholder approval, fairness opinion. Heavy dilution looms.
8-K
Reverse split approved
Onconetix stockholders approved a reverse stock split on February 3, 2026, authorizing a 1-for-2 to 1-for-50 ratio at the board's discretion within one year. The proposal passed decisively with 562,803 votes for versus 123,144 against out of over 1.5 million shares. Stockholders also greenlit potential meeting adjournments. Board picks the ratio.
8-K
CEO bonus, board votes pass
Onconetix approved a $45,000 bonus for Interim CEO Karina Fedasz, payable January 2026, and hiked her base pay by $5,000 monthly from January 1, 2026. Stockholders at the December 5 annual meeting re-elected Thomas Meier, elected Sarah Romano to the board, ratified MaloneBailey as auditors, and greenlit Series D and E PIPE share issuances under Nasdaq rules. All proposals passed decisively. Dilution looms from conversions.
8-K
PRIME Study amendment signed
Onconetix's Proteomedix subsidiary amended its license agreement with Labcorp on December 6, 2025, launching the PRIME Study—a U.S. multi-center validation of Proclarix prostate cancer risk tool in multi-ethnic cohorts. Onconetix funds it with up to $300,000 in milestone payments tied to subject enrollment, covering all costs while waiving Labcorp royalties. Labcorp shares results post-study, but restricts third-party use. Payments hinge on progress.
10-Q
Q3 FY2025 results
Onconetix posted Q3 revenue of $303.6k, down 25% y/y from $406.9k yet gross profit soared to $268.9k from $105.4k on lower cost of revenue. Operating loss narrowed to $2.1M from $2.6M amid SG&A cuts, but net loss hit $8.8M versus $3.8M due to $5.4M debt extinguishment loss and $2.5M preferred issuance charge—net exceeding operating by >20% from fair-value warrant/derivative swings. Cash ended at $0.8M after $6.6M YTD operating burn, with Series D PIPE delivering $9.3M net proceeds to settle Veru notes. Debt now $160k (insurance/Keystone, due 2025-26). Shares exploded to 1.4M weighted average from 15k y/y, driving EPS to -$6.25 from -$249 (derived). One reporting segment. Competition shadows Proclarix commercialization.
AONC
American Oncology Network, Inc.
11.12+0.00
EPIX
ESSA Pharma Inc.
0.20+0.00
IMA
ImageneBio, Inc.
6.25+0.08
LH
Labcorp Holdings Inc.
258.11-5.22
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
ONCY
Oncolytics Biotech Inc.
1.04+0.12
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
PKTX
ProtoKinetix, Inc.
0.00+0.00
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
WHWK
Whitehawk Therapeutics, Inc.
2.40+0.04